drugset / Trial / NCT01092780

Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)

NCT01092780

Phase 1 Completed 56 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

This is a study of the safety and efficacy of MK-7288 for the treatment of excessive daytime sleepiness (EDS) in participants with obstructive sleep apnea (OSA)/hypopnea syndrome (HS) who are compliant with effective nasal continuous positive airway pressure (nCPAP) therapy. The goal of this study is to determine the effect of MK-7288 after single dose administration on promoting wakefulness as measured by sleep latency on Maintenance of Wakefulness Tests, and on driving performance as measured by standard deviation of lane position in simulated driving (country vigilance driving).

Timeline

Start
2010-05-26
Primary completion
2011-05-31
Completion
2011-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-7288 Unknown 10 mg Oral
Subject MK-7288 Unknown 20 mg Oral
Subject Modafinil Small molecule 200 mg Oral

Indications